Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

Pediatric rheumatology

Feature content

09-11-2017 | Juvenile idiopathic arthritis | ACR/ARHP 2017 | Video

Internet-based educational tool improves juvenile idiopathic arthritis QoL

Study investigator Jennifer Stinson discusses a trial assessing an online program to help teenagers with juvenile idiopathic arthritis to manage their condition.

10-10-2017 | Juvenile idiopathic arthritis | Feature | Article

Talking point: Are biologics over-used in the treatment of JIA?

Timothy Beukelman speaks to medwireNews about the differing viewpoints on whether biologic treatments are over-used for the treatment of children with juvenile idiopathic arthritis.

16-08-2017 | Juvenile idiopathic arthritis | Editorial | Article

What’s in a name: The complexity of juvenile idiopathic arthritis

The complexity of juvenile idiopathic arthritis is discussed here by Editorial Board member Sangeeta Sule, focusing on how clinical decisions can be better informed in order to provide more precise and personalized treatment options.

Previous
Image Credits